达普司他：治疗慢性肾病贫血的新途径。

Q3 Pharmacology, Toxicology and Pharmaceutics

Ceska a Slovenska Farmacie Pub Date : 2024-01-01 DOI:10.36290/csf.2024.013

Viktória Paulusová, Pavel Ryšánek, Martin Šíma, Ondřej Slanař

{"title":"达普司他：治疗慢性肾病贫血的新途径。","authors":"Viktória Paulusová, Pavel Ryšánek, Martin Šíma, Ondřej Slanař","doi":"10.36290/csf.2024.013","DOIUrl":null,"url":null,"abstract":"Daprodustat: a new approach to the treatment of anemia in chronic kidney disease Daprodustat, also known under the trade name DUVROQ, is a small molecule developed by GlaxoSmithKline, which has become a promising drug in the field of anemia treatment in patients with chronic kidney disease. Daprodustat belongs to a group of drugs called hypoxia-inducible factor prolyl hydroxylase inhibitors. These drugs interfere with the regulation of erythropoietin, which is a key factor in the production of red blood cells. This drug was approved in Japan in June 2020 and clinical studies with it are ongoing in several countries around the world, where they focus on evaluating the effectiveness and safety in various populations of patients with chronic kidney disease.","PeriodicalId":38771,"journal":{"name":"Ceska a Slovenska Farmacie","volume":"73 2","pages":"110-112"},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Daprodustat: a new approach to the treatment of anemia in chronic kidney disease.\",\"authors\":\"Viktória Paulusová, Pavel Ryšánek, Martin Šíma, Ondřej Slanař\",\"doi\":\"10.36290/csf.2024.013\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Daprodustat: a new approach to the treatment of anemia in chronic kidney disease Daprodustat, also known under the trade name DUVROQ, is a small molecule developed by GlaxoSmithKline, which has become a promising drug in the field of anemia treatment in patients with chronic kidney disease. Daprodustat belongs to a group of drugs called hypoxia-inducible factor prolyl hydroxylase inhibitors. These drugs interfere with the regulation of erythropoietin, which is a key factor in the production of red blood cells. This drug was approved in Japan in June 2020 and clinical studies with it are ongoing in several countries around the world, where they focus on evaluating the effectiveness and safety in various populations of patients with chronic kidney disease.\",\"PeriodicalId\":38771,\"journal\":{\"name\":\"Ceska a Slovenska Farmacie\",\"volume\":\"73 2\",\"pages\":\"110-112\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Ceska a Slovenska Farmacie\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.36290/csf.2024.013\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Pharmacology, Toxicology and Pharmaceutics\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ceska a Slovenska Farmacie","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.36290/csf.2024.013","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}

引用次数: 0

摘要

Daprodustat，也被称为商品名DUVROQ，是由葛兰素史克公司开发的一种小分子药物，已成为慢性肾脏疾病患者贫血治疗领域的一种有前景的药物。达普司他属于缺氧诱导因子脯氨酸羟化酶抑制剂一类药物。这些药物会干扰促红细胞生成素的调节，而促红细胞生成素是红细胞生成的关键因素。该药物于2020年6月在日本获得批准，目前正在全球多个国家进行临床研究，重点是评估其在各种慢性肾脏疾病患者中的有效性和安全性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Daprodustat: a new approach to the treatment of anemia in chronic kidney disease.

Daprodustat: a new approach to the treatment of anemia in chronic kidney disease Daprodustat, also known under the trade name DUVROQ, is a small molecule developed by GlaxoSmithKline, which has become a promising drug in the field of anemia treatment in patients with chronic kidney disease. Daprodustat belongs to a group of drugs called hypoxia-inducible factor prolyl hydroxylase inhibitors. These drugs interfere with the regulation of erythropoietin, which is a key factor in the production of red blood cells. This drug was approved in Japan in June 2020 and clinical studies with it are ongoing in several countries around the world, where they focus on evaluating the effectiveness and safety in various populations of patients with chronic kidney disease.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Ceska a Slovenska Farmacie Pharmacology, Toxicology and Pharmaceutics-Pharmaceutical Science

CiteScore

0.90

自引率

0.00%

发文量

期刊介绍： Přehledový článek je zaměřen zejména na metody přípravy, charakterizaci mikročástic a dále na charakteristiku a příklady jejich možného využití ve farmakoterapii. Mikročástice jako...